<DOC>
	<DOCNO>NCT00356031</DOCNO>
	<brief_summary>The main purpose study test effectiveness bevacizumab combination radiation therapy see effect ( good bad ) patient soft tissue sarcoma . Bevacizumab antibody design specifically slow stop growth cancerous tumor decrease blood supply tumor . Bevacizumab approve FDA combination intravenous 5-fluorouracil-based chemotherapy treatment patient cancer colon rectum spread . However , use bevacizumab combination radiation sarcoma still investigation .</brief_summary>
	<brief_title>Bevacizumab Radiation Therapy Sarcomas</brief_title>
	<detailed_description>- The dose bevacizumab radiation therapy participant throughout study . - Bevacizumab give intravenous infusion every 2 week total 4 dos . - Radiation therapy begin 2 week first bevacizumab infusion deliver 5 day per week period 6 week . This do outpatient procedure . Each 2 week period consider separate treatment cycle . Participants treat radiation therapy maximum 3 cycle ( 6 week ) . - A surgeon evaluate participant tumor radiologic study study treatment determine surgical removal possible . After completion study treatment , surgeon repeat evaluation tumor . Surgery perform 6-7 week completion radiation therapy .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Primary soft tissue sarcoma ( STS ) isolate local recurrence STS . Open incisional biopsy core biopsy perform within 8 week prior registration Tumor grade intermediate high grade Tumor must locate upper extremity , low extremity , trunk , retroperitoneum , pelvis Primary tumor must &gt; 5.0cm maximal diameter local recurrence size 18 year age old Zubrod performance status 02 Adequate organ marrow function Metastatic disease Pregnant lactate woman HIV positive patient Prior treatment radiation , chemotherapy biotherapy tumor History evidence CNS disease Serious , nonhealing wound , ulcer , bone fracture Clinically significant cardiovascular disease , NYHA Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 1 year History stroke within past 6 month Major surgical procedure significant traumatic injury within 28 day Current recent ( within 10 day ) use fulldose oral parenteral anticoagulant thrombolytic agent . Presence bleed diathesis coagulopathy Proteinuria baseline clinically significant impairment renal function History abdominal fistula , gastrointestinal perforation , intaabdominal abscess within past 6 month Documented history uncontrolled seizure Grade 2 great sensory neuropathy base upon NCI CTCAE , version 3.0 Known history deep vein thrombosis pulmonary embolus Known hypercoagulable disorder History hepatic cirrhosis current hepatic dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Avastin</keyword>
</DOC>